acceptodds
Under review as a conference paper at ICLR 2027

recAMPLIFY: Large-Scale Pretraining of Recursive Protein Language Models

Abstract

Protein language models (pLMs) are powerful tools for protein annotation and mutation-effect prediction, but progress has largely depended on scaling model size and data, making them expensive and prone to memorization. Test-time scaling offers a complementary path, but methods developed for autoregressive LLMs do not transfer directly: masked encoders lack a generation loop, and amino acids do not verbalize in a reasoning language. Instead, we adapt recursive pretraining to masked pLMs, where a weight-tied Transformer core refines residue-aligned hidden states over an adjustable number of cycles. We instantiate this recipe as recAMPLIFY, a pLM with M unique parameters trained on the same T tokens as AMPLIFY-M. Despite % fewer parameters, it improves CASP contact recovery and three out of four supervised tasks, notably raising fold accuracy by %. Because optimal depth for recAMPLIFY varies across tasks and assays, we then introduce *Gated Mixture Recurrence* (GMR), a framework that decodes each protein from a probability-weighted mixture of hidden states visited during recursion. GMR employs a learned residual gate at scalar, low-rank, or per-dimension resolution to control how much of each cycle's proposed update is accepted into the state. This unifies halting and gating into a single adaptive computation objective while recovering PonderNet-style halting as a special case without gates. Layered on top of recAMPLIFY, GMR further reduces expected layer depth by up to %, although the accuracy trade-off varies by task. Mechanistic analyses show that residual gating controls recurrence stability beyond the trained depth and that halt depth tracks biological properties.

open until 14 Dec 2026

est. 32% chance this paper gets accepted at ICLR 2027.

Reject 68%Accept 32%

What do you think this paper will get?

All positions stay anonymous.

Related papers

Loading the map…

Discussion (0)

Sign in to comment.